GLYC GlycoMimetics Inc

Item 5.02  Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On June 9, 2017, the Board of Directors (the “ Board ”) of GlycoMimetics, Inc. (the “ Registrant ”) appointed Patricia S. Andrews to serve as a director of the Company and a member of the Audit Committee of the Board.  Ms. Andrews will serve as a Class III director whose term will expire at the 2020 annual meeting of stockholders.  There is no arrangement or understanding between Ms. Andrews and any other person pursuant to which she was selected as a director of the Company, and there is no family relationship between Ms. Andrews and any of the Company’s other directors or executive officers.  The Company is not aware of any transaction involving Ms. Andrews requiring disclosure under Item 404(a) of Regulation S-K. Additional information about Ms. Andrews is set forth below.

Patricia S. Andrews , age 59, has served as a member of our Board since June 2017.  Ms. Andrews has served as Chief Executive Officer of Boston Biomedical, Inc., an oncology drug research and development company, since April 2017 and previously served as its Chief Operating Officer from November 2013 to April 2017.  From October 2008 to August 2012, Ms. Andrews served as Chief Commercial Officer of Incyte Corporation, a publicly held biopharmaceutical company.  From 1991 to 2008, Ms. Andrews served in various roles of increasing responsibility at Pfizer Inc., culminating in her role as Vice President and General Manager of Pfizer’s U.S. Oncology business unit.  Ms. Andrews received her B.A. degree from Brown University and her M.B.A. degree in Finance from the University of Michigan.

In accordance with the Company’s compensation policy for non-employee directors, upon her appointment as a director, Ms. Andrews was granted a nonqualified stock option to purchase 22,000 shares of the Company’s common stock at an exercise price of $11.63, the closing price of the Company’s common stock on the date of grant.  This option will vest and become exercisable in three equal installments on the first, second and third anniversaries of the date of grant, subject to Ms. Andrews’s Continuous Service (as defined in the Company’s 2013 Equity Incentive Plan) as of each vesting date.  Additionally, Ms. Andrews will be entitled to receive a $35,000 annual retainer for her service as director and a $7,500 annual retainer for her service on the Audit Committee.  At each annual stockholder meeting following which Ms. Andrews’s term as a director continues, Ms. Andrews will be entitled to receive an additional nonqualified stock option to purchase 11,000 shares of the Company’s common stock, which option will vest and become exercisable over a one-year period following the date of grant.  Ms. Andrews has also entered into the Company’s standard form of indemnification agreement.